- Compound Camostat
- Class Binding & Internalisation Inhibitors
- Human Studies Yes
- FDA Approved N/A
Antiviral compounds are being investigated for their ability to interfere with the first stage of the viral life cycle, which is the attachment and entry of SARS-CoV-2.
Camostat: this is a serine protease inhibitor and camostat mesylate has been found to inhibit transmembrane protease serine 2 (TMPRSS2), which primes the spike glycoprotein of SARS-CoV-2 for entry.
RELATED PROJECTS
